Junctional epidermolysis bullosa
ORPHA:305Clinical groupAutosomal recessiveAdolescent, Antenatal, Infancy, Neonatal
Эпидемиология13
| Тип оценки | Класс распространённости | Среднее (на 100к) | Регион | Квалификация |
|---|---|---|---|---|
| Point prevalence | <1 / 1 000 000 | — | Worldwide | Class only |
| Point prevalence | <1 / 1 000 000 | — | Europe | Class only |
| Point prevalence | <1 / 1 000 000 | 0.08 | Sweden | Value and class |
| Point prevalence | <1 / 1 000 000 | 0.07 | Ireland | Value and class |
| Point prevalence | <1 / 1 000 000 | 0.02 | Finland | Value and class |
| Prevalence at birth | 1-9 / 1 000 000 | 0.38 | Italy | Value and class |
| Point prevalence | <1 / 1 000 000 | 0.07 | Australia | Value and class |
| Point prevalence | <1 / 1 000 000 | 0.02 | Japan | Value and class |
| Prevalence at birth | 1-9 / 1 000 000 | 0.22 | United States | Value and class |
| Point prevalence | <1 / 1 000 000 | 0.04 | United States | Value and class |
| Point prevalence | <1 / 1 000 000 | 0.07 | South Africa | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.93 | Netherlands | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.21 | Netherlands | Value and class |
Лекарства и терапия
Источник: Open Targets Platform (в реальном времени)
Клинические исследования
Источник: ClinicalTrials.gov (в реальном времени)